secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEAYA Biosciences, Inc. (IDYA)
CIK:        0001676725
Form:       8-K
Filed at:   2022-04-06T23:59:59+00:00
Accession:  0000950170-22-005384
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEAYA appoints Catherine Mackey, Ph.D. to Board of Directors
-------------------------------------------------------------

- Dr. Mackey appointed effective April 5, 2022; Board size increased from 8 to 9.
- Former SVP of Pfizer Worldwide R&D and Director of Pfizer La Jolla Laboratories; led development of Sutent, Xalkori, Ibrance.
- Received option to purchase 22,000 shares at closing price on appointment date, vesting monthly over 36 months.
- Current board seats include AVID Bioservices, Rady Children's Hospital; prior boards include Trillium, Poseida, GW Pharma.
- CEO highlights her expertise for advancing synthetic lethality pipeline including IDE397 and darovasertib.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1676725/000095017022005384/0000950170-22-005384-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1676725/000095017022005384/idya-20220405.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-005384

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer